KRAS

News

EQRx's low-price drugs mission ends with Revolution buy

EQRx's pledge to disrupt the pharma pricing system started with a clarion call in 2020 but ended with a whimper today with an agreement to be taken over by Revolution Medi

News

EMA panel rejects Mirati’s KRAS drug Krazati

Mirati Therapeutics’ hopes of an EU approval for its KRAS inhibitor Krazati in the EU have been thrown into disarray after the EMA’s human medicines committee rejected the

News

Consortium hunts new KRAS drugs with fruit flies and AI

The launch of the first drugs to inhibit the cancer-related protein KRAS was a milestone moment in oncology, but their efficacy wanes over time and tumours can develop res

News

Angion stock falls after agreeing Elicio Therapeutics merger

Angion Biomedica ended 2022 in the midst of a strategic review after its lead drug for kidney diseases flamed out, and it has now charted a path forward – a reverse merger with clinical-sta

News

Mirati challenges Amgen with FDA okay for KRAS drug

Amgen has its first direct competition in the KRAS inhibitor class following FDA approval of Mirati's adagrasib as Krazati for a form of lung cancer.

News

Sanofi backs out of $500m cancer alliance with Revolution

Sanofi has walked away from a four-year-old partnership with Revolution Medicines focused on an SHP2 inhibitor, intended as a combination with KRAS inhibitors, including Sanofi’s Mirati-par

EQRx's low-price drugs mission ends with Revolution buy

EMA panel rejects Mirati’s KRAS drug Krazati

Consortium hunts new KRAS drugs with fruit flies and AI

Angion stock falls after agreeing Elicio Therapeutics merger

Mirati challenges Amgen with FDA okay for KRAS drug

Sanofi backs out of $500m cancer alliance with Revolution

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

KRAS

Editor's Picks